Biodesix (Biodesix) Price-to-Operating-Cash-Flow : (As of May. 16, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Biodesix Price-to-Operating-Cash-Flow?

As of today (2024-05-16), Biodesix's share price is $1.535. Biodesix's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.33. Hence, Biodesix's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Biodesix's Price-to-Operating-Cash-Flow or its related term are showing as below:

BDSX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 18.295
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Biodesix's Cash Flow from Operations per share for the three months ended in Mar. 2024 was $-0.16. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.33.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 60.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 9.40% per year.

During the past 6 years, Biodesix's highest 3-Year average Operating Cash Flow per Share Growth Rate was 60.20% per year. The lowest was -31.00% per year. And the median was -15.10% per year.

Biodesix Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Biodesix's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodesix Price-to-Operating-Cash-Flow Chart

Biodesix Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Biodesix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Biodesix's Price-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, Biodesix's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biodesix's Price-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Biodesix's Price-to-Operating-Cash-Flow falls into.

Biodesix Price-to-Operating-Cash-Flow Calculation

Biodesix's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.535	/	-0.327
	=

Biodesix's Share Price of today is $1.535.
Biodesix's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.33.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Biodesix Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Biodesix's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Biodesix (Biodesix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biodesix Inc (NAS:BDSX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

2970 Wilderness Place, Suite 100, Boulder, CO, USA, 80301

Website

https://www.biodesix.com

Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Executives

Scott Hutton	director, officer: President & CEO	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Kieran O'kane	officer: Chief Commercial Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Gary Anthony Pestano	officer: Chief Development Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Robin Harper Cowie	officer: CFO, Sec'y & Treasurer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Chris Vazquez	officer: Chief Accounting Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jack W Schuler	director, 10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Jon Faiz Kayyem	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Kennedy Lawrence T. Jr	director, 10 percent owner	C/O WESTWOOD MANAGEMENT, 1700 MADISON ROAD, SUITE 200, CINCINNATI OH 45206
Ryan H Siurek	officer: Chief Accounting Officer	6200 SPRINT PARKWAY, OVERLAND PARK KS 66251
John Patience	director, 10 percent owner, other: Chairman	28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Matthew Strobeck	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Charles M Watts	director	3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Hany Massarany	director	1910 INNOVATION PARK DR, TUCSON AZ 85737
Georgantas Robert William Iii	director, officer: SVP, Rsrch & Trans'l Science	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jean M. Franchi	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139